A four to six month launch window. A four to six week MLR cycle. An average of two and a half rounds of rework. That math does not close, and most organizations are still running review models built twenty years ago. Lou Pillai reframes it: MLR was never about citations. It is a governance model for your risk posture. The leverage is upstream in modular content, not in speeding up the review meeting. For a small team commercializing for the first time, that arithmetic is fata

The entire industry agrees on where AI belongs first in a launch. Pfizer already built it, and named it after the man who founded the company. The short version: • Pfizer's Charlie is the clearest real-world proof of the MLR consensus, and it works because it routes risk to humans faster rather than deciding anything itself. • It's the lowest-regret AI win in launch, and worth building. • But the pitch assumes the review was the bottleneck, and the real delay usually sits ups

That gap, between knowing what good looks like and being able to act while the market is still moving, is what I wanted to put to someone who has lived it. Lou has spent three decades in commercialization and has since sat on the other side of the table, advising the teams making these calls. Not a vendor with a platform to sell. An operator who has watched launches drift in real time and can tell you where and why. My thanks to him for a genuinely candid hour, and for being